Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948683 · ClinicalTrials.gov registry record · Early Phase 1
Prosocial Effects of MDMA
A Early Phase 1 study of Social Interaction and MDMA ('Ecstasy'), sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05948683: Completed Early Phase 1 study of Social Interaction and MDMA ('Ecstasy'), sponsored by University of Chicago.
NCT05948683 is a Early Phase 1 study of Social Interaction and MDMA ('Ecstasy') that has completed, run by University of Chicago. The registered enrollment target is 33 participants, below the 620-participant average among 3 other Social Interaction trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948683, a Early Phase 1 study of Social Interaction and MDMA ('Ecstasy'), has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person
Primary Outcome
Differences in speech content across all conditions
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MDMA
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2024-07-15 |
| Phase | Early Phase 1 |
What the finished NCT05948683 record still lists
NCT05948683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 620-participant average among 3 other Social Interaction trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Social Interaction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05948683 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05948683 about?
NCT05948683 is a clinical study titled "Prosocial Effects of MDMA". In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person
What is the current status of trial NCT05948683?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2023-07-21. Estimated completion is 2024-07-15.
What conditions does trial NCT05948683 study?
This clinical trial studies the following conditions: Social Interaction, MDMA ('Ecstasy').
What interventions are being tested in trial NCT05948683?
The interventions under investigation include: Placebo (DRUG), MDMA (DRUG).
Who is sponsoring clinical trial NCT05948683?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948683 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Causal Effects of a Civic Engagement Intervention on Health and Wellbeing Among Youth (I-ACTED)
COMPLETED · NA
-
Strengthening Adolescent-Adult Networks to Reduce Youth Violence
COMPLETED · NA
-
Clinical Trial of a Supporter-Targeted Intervention to Improve Outcomes in Recent Sexual Assault Survivors
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI